Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02504359
Title Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

multiple myeloma

Therapies

Ixazomib

Carmustine + Cytarabine + Etoposide + Melphalan

Methotrexate + Tacrolimus

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.